Daniel J Anderson

Chief Scientific Officer at Eikon Therapeutics

Daniel J. Anderson is the Chief Scientific Officer at Eikon Therapeutics, a position he has held since December 2020. In this role, he focuses on integrating engineering principles into drug discovery to develop impactful treatments for patients. Prior to this, he served as the Senior Vice President of Biology at Eikon Therapeutics from October 2019 to December 2020, where he worked on visualizing protein motion in live cells to discover drugs for diseases with unmet needs.1 2

Career Background

Vice President of Biology at Recursion Pharmaceuticals (July 2018 - September 2019)
Senior Director of Biology at Recursion Pharmaceuticals (August 2017 - July 2018)
Director of Biology at Cleave Biosciences, Inc. (March 2012 - July 2017)
Senior Research Associate at Genentech (January 2009 - January 2012)
Researcher at the Salk Institute (May 2005 - January 2009)
Undergraduate Researcher at the University of Pittsburgh (September 2000 - May 2004)

Education

Bachelor of Science in Biology, University of Pittsburgh (2000 - 2004)
PhD in Cell Biology / Microscopy, UC San Diego (2004 - 2008)

Anderson is recognized for his leadership and scientific expertise in the biotechnology field, with a strong emphasis on team building and innovation in drug discovery.1 2 3

Experience

Chief Scientific Officer at Eikon Therapeutics (December 2020 - Present)

Senior Vice President, Biology at Eikon Therapeutics (October 2019 - December 2020); Vice President, Biology at Recursion Pharmaceuticals (July 2018 - September 2019); Senior Director, Biology at Recursion Pharmaceuticals (August 2017 - July 2018); Director of Biology at Cleave Biosciences, Inc. (March 2012 - July 2017); Senior Research Associate at Genentech (January 2009 - January 2012); Researcher at Salk Institute (May 2005 - January 2009); Researcher at University of Pittsburgh (September 2000 - May 2004); Researcher at University of Pennsylvania (June 1999 - August 2000)